
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is a established genetic diagnostic and research company with strong financials and growth potential in the genomic profiling market, specifically in prenatal and cancer testing. Despite facing competition and risks in expanding internationally, Natera has shown success and potential in securing contracts and launching new tests. They also have a focus on changing disease management and revenue growth in non-covered indications, with promising results in organ transplant monitoring and improving outcomes for certain cancer patients.
Bears say
Natera is a leader in the highly competitive diagnostic and research industry, but faces risks such as potential regulatory hurdles and reliance on lab partnerships. The company's strong competition in the prenatal and oncology markets may make it difficult to secure market share. Additionally, factors such as seasonality, changing reimbursement rates, and reliance on Medicaid may negatively impact Natera's financial performance in the future.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares